READ THIS NEXT: If You Have Any of These Colgate Toothpastes, Get Rid of Them, FDA Warns. Just like food and beverage products, over-the-counter (OTC) and prescription medications are subject to recalls when their safety comes into question, including a few that have taken place recently. In July, Tennessee-based Vi-Jon, LLC announced it had expanded an initial voluntary recall of its Magnesium Citrate Saline Laxative Oral Solution for the third time. The update added 63 new products, including grape-, lemon-, and cherry-flavored versions of the medication sold to CVS, Walgreens, and Rite Aid stores nationwide, as well as Walmart, Publix, Kroger, Harris Teeter, and others. The company says it pulled the product after third-party testing came back positive for Gluconacetobacter liquefaciens bacteria. The FDA also announced in July that Family Dollar had issued an expansive recall of 430 toiletries, hygiene products, and OTC medications. The affected products filled up 11 pages of a document, including popular name brands such as Dayquil, Colgate, Listerine, Crest, Arm & Hammer, Icy Hot, Suave, Purell, Dial, St. Ives, Secret, Coppertone, Dove, Blistex, Tylenol, Neutrogena, and more. The company said the products had been “stored outside of labeled temperature requirements” and “inadvertently shipped to certain stores” between May and June. And on Sept. 26, the health agency alerted the public to another recall, this time from New Jersey-based Eugia US LLC (formerly AuroMedics Pharma LLC) for one lot of is AuroMedics Acyclovir Sodium Injection 500 mg per 10 mL (50 mg/mL), 10 mL single-dose vial, also known by the brand name Zovirax. The company said customer complaints noting “the presence of dark red, brown and black particulate inside the vial” led to the medication’s recall, which is used to treat the herpes virus. But now, officials are warning of another potential health risk linked to popular medications. On Sept. 29, the FDA announced that Golden State Medical Supply, Incorporated (GSMS, Inc.) had issued a voluntary recall for two of its prescription medications, Clopidogrel 75mg Tablets and Atenolol 25mg Tablets. The affected products were initially sold in 1,000-count bottles with the expiration date 12/2023.ae0fcc31ae342fd3a1346ebb1f342fcb The company says it initiated the recall “out of an abundance of caution” after receiving a report that a bottle containing Clopidogrel 75mg Tablets was mislabeled as Atenolol 25mg Tablets. The agency’s notice specifies that the recall only affects products with lot number GS046745 and that no other Clopidogrel or Atenolol products sold by GSMS are included. RELATED: For more up-to-date information, sign up for our daily newsletter. According to the FDA, atenolol is a prescription drug used to lower blood pressure in the treatment of hypertension. On the other hand, doctors prescribe clopidogrel to patients to reduce the risk of stroke, blood clot, or “serious heart problem for patients who have had [a] heart attack, severe chest pain, or circulation problems” as listed on the product’s label. The agency warns that the labeling mixup could lead patients taking atenolol to suddenly stop receiving their dosage, increasing the risk for heart attack, as well as “hypertensive and arrhythmic adverse events” due to the rapid withdrawal from the effects of the medication. The notice also points out that patients prescribed atenolol often take other anticoagulant and antiplatelet medications that could significantly increase their risk for bleeding if they unknowingly add it to their daily regimen. The FDA reports that the affected lots mainly were sold to wholesalers AmerisourceBergen and McKesson and that GSMS has since instructed them to quarantine and stop distributing the products. They’ve also told the companies to notify all customers—including pharmacies and consumers—by sending them a copy of the recall notice, as well as a “recall response form, and letter to consumers, patients, and caregivers.” Patients with any questions are urged to contact their doctor or healthcare provider. Customers can also reach GSMS by calling the phone number listed on the FDA’s notice.
